Biopharmaceutics and therapeutic potential of engineered nanomaterials
- PMID: 18855608
- PMCID: PMC2715162
- DOI: 10.2174/138920008786049230
Biopharmaceutics and therapeutic potential of engineered nanomaterials
Abstract
Engineered nanomaterials are at the leading edge of the rapidly developing nanosciences and are founding an important class of new materials with specific physicochemical properties different from bulk materials with the same compositions. The potential for nanomaterials is rapidly expanding with novel applications constantly being explored in different areas. The unique size-dependent properties of nanomaterials make them very attractive for pharmaceutical applications. Investigations of physical, chemical and biological properties of engineered nanomaterials have yielded valuable information. Cytotoxic effects of certain engineered nanomaterials towards malignant cells form the basis for one aspect of nanomedicine. It is inferred that size, three dimensional shape, hydrophobicity and electronic configurations make them an appealing subject in medicinal chemistry. Their unique structure coupled with immense scope for derivatization forms a base for exciting developments in therapeutics. This review article addresses the fate of absorption, distribution, metabolism and excretion (ADME) of engineered nanoparticles in vitro and in vivo. It updates the distinctive methodology used for studying the biopharmaceutics of nanoparticles. This review addresses the future potential and safety concerns and genotoxicity of nanoparticle formulations in general. It particularly emphasizes the effects of nanoparticles on metabolic enzymes as well as the parenteral or inhalation administration routes of nanoparticle formulations. This paper illustrates the potential of nanomedicine by discussing biopharmaceutics of fullerene derivatives and their suitability for diagnostic and therapeutic purposes. Future direction is discussed as well.
Figures


Similar articles
-
Medicinal applications of fullerenes.Int J Nanomedicine. 2007;2(4):639-49. Int J Nanomedicine. 2007. PMID: 18203430 Free PMC article. Review.
-
Carbon nanomaterials: Biologically active fullerene derivatives.Srp Arh Celok Lek. 2016 Mar-Apr;144(3-4):222-31. Srp Arh Celok Lek. 2016. PMID: 27483572 Review.
-
Biomedical Applications of Nanomaterials as Therapeutics.Curr Med Chem. 2018;25(12):1409-1419. doi: 10.2174/0929867324666170331120328. Curr Med Chem. 2018. PMID: 28393698 Review.
-
Recent Advances in Nanomaterials Development for Nanomedicine and Cancer.ACS Appl Bio Mater. 2021 Aug 16;4(8):5908-5925. doi: 10.1021/acsabm.1c00591. Epub 2021 Jul 19. ACS Appl Bio Mater. 2021. PMID: 35006909 Review.
-
2D Nanomaterials for Cancer Theranostic Applications.Adv Mater. 2020 Apr;32(13):e1902333. doi: 10.1002/adma.201902333. Epub 2019 Jul 28. Adv Mater. 2020. PMID: 31353752 Review.
Cited by
-
The effect of glycyrrhizin acid on Bax and Bcl2 expression in hepatotoxicity induced by Titanium dioxide nanoparticles in rats.Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):168-176. Gastroenterol Hepatol Bed Bench. 2020. PMID: 32308939 Free PMC article.
-
Controlled Drug Release from Nanoengineered Polysaccharides.Pharmaceutics. 2023 Apr 28;15(5):1364. doi: 10.3390/pharmaceutics15051364. Pharmaceutics. 2023. PMID: 37242606 Free PMC article. Review.
-
Nanomaterials, inflammation, and tissue engineering.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 May-Jun;7(3):355-70. doi: 10.1002/wnan.1320. Epub 2014 Nov 25. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015. PMID: 25421333 Free PMC article. Review.
-
Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes.Int J Nanomedicine. 2011;6:2779-90. doi: 10.2147/IJN.S25534. Epub 2011 Nov 8. Int J Nanomedicine. 2011. PMID: 22128249 Free PMC article.
-
A novel method for PEGylation of chitosan nanoparticles through photopolymerization.RSC Adv. 2019 May 7;9(25):14011-14015. doi: 10.1039/c9ra00780f. eCollection 2019 May 7. RSC Adv. 2019. PMID: 35519348 Free PMC article.
References
-
- Whitesides GM. The ‘right’ size in nanobiotechnology. Nat. Biotechnol. 2003;21:1161–1165. - PubMed
-
- Seaton A, Donaldson K. Nanoscience, nanotoxicology, and the need to think small. Lancet. 2005;365:923–924. - PubMed
-
- Mazzola L. Commercializing nanotechnology. Nat. Biotechnol. 2003;21:1137–1143. - PubMed
-
- Paull R, Wolfe J, Hebert P, Sinkula M. Investing in nanotechnology. Nat. Biotechnol. 2003;21:1144–1147. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources